| Abstract: |
Human tumors express high levels of growth factors and their receptors, andmany types of malignant cells appear to exhibit autocrine- or paracrine-stimulated growth. Therefore, antireceptor directed therapies have the potential of being useful anti-cancer agents. A series of murine monoclonal antibodies (MAbs) directed against human growth factor receptors and their corresponding growth factors have been produced. MAbs against the receptors for epidermal growth factor, Her2/Neu, transferrin, insulin-like growth factor, interleukin, (IL)-2 and IL-1 are currently evaluated. MAbs directed against epidermal growth factor, transforming growth factor-ga, bombesin, IL-2, an dIL-6 also are under study. These MAbs have shown promising preclinical activity, and some of them are being tested in clinical trials. So far, anti-tumor responses have been observed with anti-IL-2 receptor, anti-bombesin and anti-IL-6 MAbs. Further research is focusing in the production of "chimeric" and "humanized" MAbs, in order to obviate the problem of host immune reactions. © 1994. |
| Keywords: |
epidermal growth factor; somatomedin; cisplatin; doxorubicin; antineoplastic agents; combined modality therapy; chemotherapy; antineoplastic agent; neoplasms; animal; interleukin 2; epidermal growth factor receptor; cancer therapy; monoclonal antibodies; monoclonal antibody; antibodies, monoclonal; interleukin 6; tumor; clinical trials; transferrin; interleukin 1; receptors, growth factor; growth substances; human; priority journal; article; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; growth factor receptors
|
